Resverlogix Conference Call & Webcast Announcement

TSX Exchange Symbol: RVX

CALGARY, Feb. 6, 2014 /CNW/ - Resverlogix Corp. (TSX:RVX) will be hosting a conference call and webcast on Thursday, February 13, 2014 at 11 am MDT / 1 pm ET. The call will update the market on current clinical and business structure options.

Details for the conference call and webcast are as follows:

Link to webcast:

Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340  

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on our blog at and our IR App found on Apple products iTunes and Android users (Google Play).

Company Contacts:        
Donald J. McCaffrey   
President and CEO    
Resverlogix Corp.   
Phone: 403-254-9252   
      Kenneth Lebioda   
SVP Business & Corporate Development
Resverlogix Corp.
Phone: 403-254-9252


SOURCE: Resverlogix Corp.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890